VEGFA and non-small cell lung carcinoma: Notable examples include MP-0250, a VEGF/HGF-targeting PDC designed via AlphaFold2-guided peptide-receptor docking, which demonstrated 34% objective response in Phase II Non-Small Cell Lung Cancer (NSCLC) trials (NCT04088664), and AI-refined somatostatin analogs in Lutathera® that reduced hepatotoxicity by 22% post-FDA approval (Quan et al., 2020; Morgan et al., 2023).